CLOVER HEALTH INVESTMENTS CO (CLOV)
US18914F1030 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to CLOV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.79. This target is -16.9% below the current price.
CLOV was analyzed by 9 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CLOV.
In the previous month the buy percentage consensus was at a similar level.
CLOV was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-10-07 | UBS | Initiate | Neutral |
| 2023-08-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2023-03-06 | Canaccord Genuity | Maintains | Buy |
| 2023-03-06 | Credit Suisse | Maintains | Underperform |
| 2022-11-16 | Citigroup | Maintains | Neutral |
| 2022-11-08 | SVB Leerink | Maintains | Market Perform |
| 2022-08-09 | Credit Suisse | Maintains | Underperform |
| 2022-08-09 | Citigroup | Maintains | Neutral |
| 2022-05-10 | SVB Leerink | Maintains | Market Perform |
| 2022-02-25 | SVB Leerink | Maintains | Market Perform |
| 2022-02-02 | Cowen & Co. | Upgrade | Underperform -> Market Perform |
| 2022-02-02 | Canaccord Genuity | Initiate | Buy |
| 2022-01-19 | SVB Leerink | Initiate | Market Perform |
| 2022-01-07 | Credit Suisse | Downgrade | Neutral -> Underperform |
| 2021-11-15 | Credit Suisse | Maintains | Neutral |
| 2021-09-10 | Cowen & Co. | Initiate | Underperform |
| 2021-07-12 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-06-10 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2021-05-19 | Credit Suisse | Maintains | Neutral |
| 2021-05-17 | B of A Securities | Downgrade | Buy -> Neutral |
| 2021-03-09 | Credit Suisse | Initiate | Neutral |